Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease
Autor: | Salvatore P. Costa, Mandeep S. Sidhu, Robert S. Rosenson, Sripal Bangalore, Roy O. Mathew, Radmila Lyubarova, Rafia I Chaudhry |
---|---|
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
medicine.medical_specialty medicine.medical_treatment Population Hyperlipidemias 030204 cardiovascular system & hematology urologic and male genital diseases Niacin End stage renal disease 03 medical and health sciences 0302 clinical medicine Ezetimibe Renal Dialysis Risk Factors Internal medicine Hyperlipidemia medicine Humans Pharmacology (medical) Renal Insufficiency Chronic education Dialysis Hypolipidemic Agents Randomized Controlled Trials as Topic Pharmacology education.field_of_study business.industry PCSK9 Inhibitors Fibric Acids Patient Acuity General Medicine Atherosclerosis medicine.disease Lipids female genital diseases and pregnancy complications Clinical trial 030104 developmental biology Practice Guidelines as Topic Hydroxymethylglutaryl-CoA Reductase Inhibitors Proprotein Convertase 9 Cardiology and Cardiovascular Medicine business Dyslipidemia Glomerular Filtration Rate Kidney disease medicine.drug |
Zdroj: | Cardiovascular Drugs and Therapy. 35:479-489 |
ISSN: | 1573-7241 0920-3206 |
Popis: | Atherosclerotic cardiovascular disease (ASCVD) remains an important contributor of morbidity and mortality in patients with chronic kidney disease (CKD). CKD is recognized as an important risk enhancer that identifies patients as candidates for more intensive low-density lipoprotein (LDL) cholesterol lowering. However, there is controversy regarding the efficacy of lipid-lowering therapy, especially in patients on dialysis. Among patients with CKD, not yet on dialysis, there is clinical trial evidence for the use of statins with or without ezetimibe to reduce ASCVD events. Newer cholesterol lowering agents have been introduced for the management of hyperlipidemia to reduce ASCVD, but these therapies have not been tested in the CKD population except in secondary analyses of patients with primarily CKD stage 3. This review summarizes the role of hyperlipidemia in ASCVD and treatment strategies for hyperlipidemia in the CKD population. |
Databáze: | OpenAIRE |
Externí odkaz: |